.... Recent evidence shows that eEF2K plays an important role in learning and memory, processes that require the synthesis of new proteins and involve Ca-mediated signalling. eEF2K is activated under conditions of nutrient and energy depletion. In cancer cells, or certain tumours, eEF2K exerts cytoprotective...

...Neil R. Smith; Stephen R. Wedge; Aurelien Pommier; Simon T. Barry There has been significant investment in developing novel therapies to target solid tumour vasculature. Different technical approaches have been utilized with the aim of inhibiting tumour angiogenesis or compromising the function...

... of the current understanding of the formation, functional abnormalities and specific gene expression of glioblastoma vessels and the consequences of vascular abnormalization for the tumour microenvironment. 1 email anna.dimberg@igp.uu.se 13 10 2014 © The Authors Journal compilation ©...

... affects tumour angiogenesis and cancer progression. Revisiting the fundamental biology behind how this integrin regulates tumour growth and angiogenesis, we believe, is the key not only to understanding how angiogenesis is normally co-ordinated, but also in success with drugs directed against...

...Thaned Kangsamaksin; Ian W. Tattersall; Jan Kitajewski The Notch signalling pathway is a key regulator of developmental and tumour angiogenesis. Inhibition of Delta-like 4 (Dll4)-mediated Notch signalling results in hyper-sprouting, demonstrating that Notch regulates tip-stalk cell identity...

... copy number increase in the human population appears to be approximately 2% and may be linked to a risk of obesity, diabetes and aging. Increased GLO1 copy number has been found in human tumour cell lines and primary human tumours. The minimum common copy number increase region was approximately 1 Mb...

... overview of this and other similarities between the metabolism in tumours and early embryos and proposes whether knowledge of early embryo metabolism can help us to understand metabolic regulation in cancer cells. 1 To whom correspondence should be addressed (email roger.sturmey@hyms.ac.uk...

...Monika Baj-Krzyworzeka; Jarosław Baran; Rafał Szatanek; Bożenna Mytar; Maciej Siedlar; Marek Zembala The tumour microenvironment represents a dynamic complex milieu, which includes tumour cells, cells of the immune system and other (cellular and non-cellular) components. The role...

... of cisplatin treatment on microRNA expression, and the ability of microRNAs to modulate cisplatin resistance. 1 email r.m.drayton@sheffield.ac.uk 17 5 2012 © The Authors Journal compilation © 2012 Biochemical Society 2012 cisplatin microRNA (miRNA) protein expression tumour...

...Chern Ein Oon; Adrian L. Harris Notch signalling is a key pathway controlling angiogenesis in normal tissues and tumours. This has become a major focus of development of anticancer therapy, but to develop this appropriately, we need further understanding of the mechanisms of regulation of Dll4...

...-glycosylation and tumorigenesis, as changes in tumour environment and cell adhesion are hallmarks of cancer progression. 31 8 2010 RNAi (RNA interference) to pgant3 in vivo was also employed to confirm a role for pgant3 in wing integrity [ 20 ]. After crossing two independent UAS- pgant3 IR...

... in determining the level of ERβ protein expression. We have also shown that these alternative ERβ 5′-UTRs have a tissue-specific distribution and are differentially expressed between various normal and tumour tissues. Our results also suggest that alternative 5′-UTRs can influence downstream splicing events...

... various tumour conditions in mice. As predicted, we were able to identify various PKC isoforms to be either up- or down-regulated during the development and progression of certain tumours, implying that these isoforms are substantially linked to the biology of these tumours. In order to prove...

...W.-B. Wu; H.-S. Chiang; J.-Y. Fang; C.-F. Hung Tumours are complex tissues composed of both matrix proteins and stromal cells such as fibroblasts and inflammatory cells. Tumour progression is often the result of dynamic interactions between the tumour cells and their surroundings. Lycopene...

... transactivator of transcription (Tat) tumour Over the last decade, CPPs, including Tatp (transactivator of transcription peptide) and various oligoarginines, have been widely exploited for the intracellular delivery of differently sized cargo in a range of cell types, both in vitro and in vivo...

... or tumour growth. Since the intestine has the highest metabolic activity of all the internal organs, a tumour will initially compete with the gut for nutrients and energy-providing molecules. The polyamines represent a class of molecules where the demand in the body increases during tumour growth. A tumour...

... resistance. 1 To whom correspondence should be addressed (email eric.lam@imperial.ac.uk ). 30 6 2006 © 2006 The Biochemical Society 2006 cell fate forkhead box O (FOXO) phosphoinositide 3-kinase (PI3K) phosphorylation tumour The PI3K signal transduction pathway...

... the developmental origin of LSCs and the mechanisms responsible for their emergence in the course of the disease. This report will review our current knowledge on LSC development and finally demonstrate how these discoveries provide a paradigm for identification of CSCs from solid tumours. 1 To whom...

...J.M. Teodoridis; G. Strathdee; J.A. Plumb; R. Brown Aberrant methylation of CpG islands (CpG-rich regions of DNA associated with the promoters of many genes) is associated with transcriptional inactivation of genes involved in tumour development. Genes involved in key DNA damage response pathways...

... was found in drug-resistant tumour cells and may be an example of an undesirable effect of the enzymatic protection against DNA glycation. Experimental overexpression of glyoxalase I conferred resistance to drug-induced apoptosis. Glyoxalase I-mediated drug resistance was found in human leukaemia and lung...

...M. T. Sampson; A. K. Kakkar Tumours are capable of activating blood coagulation through the expression of procoagulant molecules such as tissue factor, cancer procoagulant and hepsin. Initiation of the clotting cascade results in the generation of the activated serine proteases factor VIIa, factor...

...M. E. Maragoudakis; N. E. Tsopanoglou; P. Andriopoulou Clinical, laboratory, histopathological and pharmacological evidence support the notion that a systemic activation of blood coagulation is often present in cancer patients. Additionally, thrombin was shown to promote tumour progression...